Developing BET-ter treatments for cutaneous T-cell lymphoma

No abstract is available for this paper.

• Publication year

  2019

• Venue

  OncoTarget

• Publication date

  2019-02-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.18632/oncotarget.26662PMID 30863486PMCID 6407685
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combinatorial chemistry in drug discovery.

  2017cited by this paper
• How I treat mycosis fungoides and Sézary syndrome.

  2016cited by this paper
• Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

  2015cited by this paper
• Genomic landscape of cutaneous T cell lymphoma

  2015cited by this paper
• Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes

  2015cited by this paper
• Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.

  2014cited by this paper
• Evolving Insights in the Pathogenesis and Therapy of Cutaneous T‐cell lymphoma (Mycosis Fungoides and Sezary Syndrome)

  2011cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.

  2010cited by this paper
• How I treat mycosis fungoides and Sézary syndrome.

  2009cited by this paper

• No citing papers are available for this paper.